How Eli Lilly's GLP-1 portfolio sales may aid upcoming Q3 results
FROM THE WIRE · FINANCE.YAHOO.COM
Eli Lilly LLY is a dominant player in the cardiometabolic market, backed by a strong and expanding GLP-1 portfolio. Its GLP-1 lineup includes Mounjaro and Zepbound (tirzepatide injections) for type II diabetes (T2D) and obesity, respectively, and the newly approved oral obesity…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishMounjaro and Zepbound drive Lilly's growth, making the October 29 results relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01In the first half of 2026, Mounjaro and Zepbound generated $27.7 billion in combined sales.
- 02Sales grew about 88% year over year.
- 03Lilly will report third-quarter results on October 29, 2026.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Eli Lilly and Company1,246.82 USD-0.68%today -0.81%Positive Novo Nordisk A/S38.52 USD-0.27%today -0.81%Neutral Viking Therapeutics, Inc.25.41 USD-0.39%today +0.95%Neutral Structure Therapeutics Inc.21.45 USD-1.29%today +1.76%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets